首页> 外文OA文献 >Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

【2h】

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

机译：一项随机，安慰剂对照，双盲研究的研究设计和理论基础，以评估塞卢替尼（AZD6244; ARRY-142886）联合达卡巴嗪在转移性葡萄膜黑色素瘤（SUMIT）患者中的疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Richard D. Carvajal; Gary K. Schwartz; Helen Mann; Ian Smith; Paul D. Nathan;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类
入库时间 2022-08-20 20:26:28

相似文献

外文文献
中文文献

1. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. [J] . Gy?rgy Bodoky, Constanta Timcheva, David Robert Spigel, Investigational new drugs. . 2012,第3期

机译：II期开放标签随机研究，评估一线吉西他滨治疗失败的晚期或转移性胰腺癌患者中selumetinib（AZD6244 [ARRY-142886]）与卡培他滨的疗效和安全性。
2. SELECT-2: A phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer [J] . Soria, J.-C., Fül?p, Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第12期

机译：SELECT-2：II期，双盲，随机，安慰剂对照研究，以评估SELUMETINIB PLUS DOCETAXEL作为先进或转移性非小细胞肺癌患者的二线治疗的疗效
3. Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer [J] . Bendell Johanna C., Ervin Thomas J., Gallinson David, Clinical colorectal cancer . 2013,第3期

机译：一项随机，双盲，安慰剂对照的II期研究的治疗依据和研究设计，该研究评估了Onartuzumab（MetMAb）与Bevacizumab加mFOLFOX-6联合治疗先前未接受治疗的转移性结直肠癌患者的疗效
4. A Randomized, Placebo-Controlled Study of the Efficacy of Cognitive Intervention on Elderly People and on Patient's with Alzheimer's Disease [C] . J.J. Yanguas, C. Buiza, I. Etxeberria, International Conference on Computers Helping People with Special Needs(ICCHP 2006); 20060711-13; Linz(AT) . 2006

机译：认知干预对老年人和阿尔茨海默氏病患者疗效的随机，安慰剂对照研究
5. Study design and rationale for a randomised placebo-controlled double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT) [O] . Richard D. Carvajal, Gary K. Schwartz, Helen Mann, 2015

机译：一项随机安慰剂对照双盲研究的研究设计和理论基础以评估塞卢替尼（AZD6244; ARRY-142886）联合达卡巴嗪在转移性葡萄膜黑色素瘤（SUMIT）患者中的疗效
6. Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 ARRY-142886) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy [O] . György Bodoky, Constanta Timcheva, David Robert Spigel, 2011

机译：错误至：II期开放标签随机研究，以评估Selumetinib（AZD6244 Arry-142886的疗效和安全性与患有失败的一线吉西他滨治疗失败或转移性胰腺癌的患者

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

著录项

相似文献

相关主题

期刊订阅